Alpha Teknova Stock Performance and Recent Corporate Actions
Market Snapshot (24‑hour period ending 11:21 PM Central Europe, Thursday 22 Oct 2026)
| Item | Value |
|---|---|
| Closing price | USD 6.15 |
| Daily change | –20.84 % |
| 24‑hour volume | USD 33.4 mn |
| Market capitalization | USD 396.8 mn |
| Shares outstanding | 53.7 mn |
| 200‑day simple moving average | USD 4.78 |
| 52‑week high | USD 9.48 (25 Sep 2026) |
| 52‑week low | USD 1.91 (17 Feb 2026) |
| Cumulative decline since last month‑end | –33.3 % |
Recent Corporate Event
Alpha Teknova, Inc. (Nasdaq: TKNO) announced an underwritten public offering of 8 million shares of common stock at a public price of USD 5.00 per share.
- Regulation: Offer conducted under an effective Form S‑3 registration.
- Closing Date: Expected around 22 Oct 2026.
- Gross Proceeds: Approximately USD 40 mn before underwriting discounts and commissions.
- Additional Shares: Underwriters hold a 30‑day option to purchase up to 1.2 million additional shares.
- Use of Proceeds: General corporate purposes, including potential debt repayment and investments in complementary businesses.
Preliminary Third‑Quarter 2026 Financial Update
| Metric | Result |
|---|---|
| Revenue growth YoY | ~20 % |
| Gross margin | Expanded |
| Adjusted EBITDA | Negative (due to ongoing investment) |
| Cash and short‑term investments | ~USD 16.6 mn |
| Note | Unaudited figures; final results may differ upon formal report release. |
Peer Performance (Last 24 Hours)
| Company | Ticker | Change | Current Price | Market Capitalization |
|---|---|---|---|---|
| Diamedica Therapeutics | DMAC | +0.23 % | USD 8.63 | USD 468.6 mn |
| Crane Harbor Acquisition | CRAN | 0 % | USD 10.09 | USD 473.2 mn |
| Rayonier Advanced Materials | RYAM | –0.14 % | USD 6.83 | USD 473.5 mn |
| Vireo Growth | VREOF | –1.92 % | USD 8.50 | USD 470.8 mn |
| Sight Sciences | SGHT | +0.93 % | USD 9.09 | USD 474.9 mn |
Company Profile
Alpha Teknova, Inc. is a biotechnology firm listed on Nasdaq that focuses on discovery, research, development, and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics. The company serves a global customer base. Further information is available on the company’s website: www.teknova.com .
